Clinical trial · no report yet · Phase 2
PAVO
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
- NCT05169437 ↗
- Terminated
- Tempus AI
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Solid Tumor; Breast Tumor; Colon Tumor, Malignant; Lung Tumor; Urologic Cancer; Pancreatic Cancer; Melanoma; Metastatic Cancer; Locally Advanced Solid Tumor; Esophageal Cancer; Endometrial Cancer; Head and Neck Cancer
- Interventions
- Niraparib
- Arms
- Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations · Experimental
- Enrollment
- 22
- Primary outcomes
- Overall Response Rate (ORR) - Independent Central Review (ICR)
- Sponsor
- Tempus AI with GlaxoSmithKline
- Start
- Mar 15, 2022
- Primary completion
- Aug 6, 2024
- Results posted
- Yes
- Registry record
- NCT05169437 · updated Oct 29, 2025